Figure 11
An activation index consisting of inflammatory cytokines and surface markers, CD40, CD80, CD86 and MHC II predicts 8/10 liposome formulations accurately for in vivo efficacy. Figure showing all 10 liposomes and their in vitro strength categorised as a percentage response of DDA:TDB, where ‘+++’ ≥ 80%, ‘++’ 50–79%, ‘+’ < 50%. (a) shows liposomes categorised using the in vitro activation index consisting of an average of CD40, CD80, CD86 and MHC II (in which expression for each individual marker was determined as the product of percentage positive and MFI) and TNF-α, IL-8 and IL-1β. The table in (b) shows the liposomes’ in vitro strength obtained from the activation index in (a) against the in vivo IFN-ү strength.
